Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations

BRAF-V600 mutations occur in approximately 50% of patients with metastatic melanoma. Immune-checkpoint inhibitors and targeted therapies are both active as first-line treatments in these patients regardless of their mechanisms of action and toxicities. However, an upfront therapeutic strategy is sti...

Full description

Saved in:
Bibliographic Details
Published in:Ther Adv Med Oncol
Main Authors: Giunta, Emilio Francesco, De Falco, Vincenzo, Napolitano, Stefania, Argenziano, Giuseppe, Brancaccio, Gabriella, Moscarella, Elvira, Ciardiello, Davide, Ciardiello, Fortunato, Troiani, Teresa
Format: Artigo
Language:Inglês
Published: SAGE Publications 2020
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7307282/
https://ncbi.nlm.nih.gov/pubmed/32612709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920925219
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items